We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cancer Therapeutic Found in Green Tea

By Biotechdaily staff writers
Posted on 31 May 2005
Green tea seems to protect against cancer by affecting a "promiscuous” protein that pharmacology researchers are now targeting in an effort to develop a new agent to stop the disease, according to a new study.

The study supports beliefs about the health benefits of green tea with definitive scientific findings. More...
The new findings were incorporated into a thesis by Christine Palermo, a student at the University of Rochester (NY, USA). Whereas it has been reported that green tea protects individuals against various types of cancer, including liver and breast cancer, precisely how it does this is as yet unknown.

"It's important to find out the source of green tea's protective effects,” stated Thomas A. Gasiewicz, Ph.D., a toxicologist from the University of Rochester, who has long studied the harmful effects of dioxin, which eventually led him to explore the protective effects of green tea. "What is exciting here is that a complete new mechanism has been found that very well could be responsible for its protective effects, and that could help us find a compound that is much more potent.”

The University of Rochester researchers have discovered a chaperone protein known as HSP90, found to be involved in conferring green tea's protective effects. Other scientists have demonstrated that many cancer cells have an increase in the level of HSP90 compared to normal cells, and that when HSP90 is blocked, levels of proteins that make cancer cells grow decrease.

Pharmaceutical companies are currently studying ways to block HSP90, which is known as a promiscuous chaperone protein because it binds to many different cells and receptors in the body. It now appears that these scientists are trying to duplicate what green tea does naturally. Dr. Gasiewicz reported that pharmaceutical companies can learn from green tea, which might modulate HSP90 in a manner that scientists have not seen before.
Dr. Gasiewicz has long studied how dioxin and other compounds such as cigarette smoke manipulate a key cancer-causing molecule, the aryl hydrocarbon (AH) receptor, which typically plays a role in activating genes that are frequently harmful.

In 2003, the University of Rochester scientists discovered that AH activity is suppressed by a chemical found in green and white teas, epigallocatechingallate (EGCG), a relative of a flavonoid found in cabbage, broccoli, grapes, and red wine that are known to help prevent cancer. The investigators had been working on other compounds in an attempt to block AH activity.

"We initially hypothesized that EGCG would work in the same way as other AH antagonists, by binding directly to it. We were completely surprised that this isn't the case,” remarked Dr. Gasiewicz. The researchers discovered that EGCG binds to HSP90, a protein that helps other proteins remain stable, serving the same role as a kite's tail. When the two bind, HSP90 no longer activates the AH receptor, blocking the cascade of events that would lead to the activation of several harmful genes.




Related Links:
University of Rochester

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.